BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...

BioNTech, the German pharmaceutical company, announced on Wednesday that it has reached an agreement to acquire Biotheus, a ...

BioNTech, the German developer of a widely used mRNA vaccine for the coronavirus, agreed to pay US$800 million (HK$6.24 billion) to buy biotech company Biotheus, a developer of cancer drugs. In a ...

BioNTech SE BNTX announced that it has entered into a definitive agreement to acquire China-based biotech, Biotheus, to ...

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Instil Bio (TIL – Research Report) today and set a price target of ...

H.C. Wainwright lowered the firm’s price target on Instil Bio (TIL) to $110 from $120 and keeps a Buy rating on the shares post the Q3 ...

Summit and Akeso's ivonescimab attracted headlines earlier this year when it was shown to be more effective than anti-PD-1 ...

(MENAFN) BioNTech signed an agreement to buy Biotheus, which is a Chinese biotechnology firm, for USD800 million to further enhance its treatment of tumors, stated the German medicinal producer ...

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

Vaccine maker shares closed lower Thursday amid reports that Donald Trump was set to nominate vaccine critic Robert F.

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...